HRICKOVÁ, Mária, Petra AMCHOVÁ and Jana RUDÁ. The Effect of CNQX on Self-Administration: Present in Nicotine, Absent in Methamphetamine Model. FRONTIERS IN BEHAVIORAL NEUROSCIENCE. LAUSANNE: FRONTIERS MEDIA SA, 2024, vol. 17, January 2024, p. 1-10. ISSN 1662-5153. Available from: https://dx.doi.org/10.3389/fnbeh.2023.1305412.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name The Effect of CNQX on Self-Administration: Present in Nicotine, Absent in Methamphetamine Model
Name in Czech Vliv CNQX na autoaplikaci: U nikotinového modelu je přítomen, u metamfetaminového chybí
Authors HRICKOVÁ, Mária (703 Slovakia, belonging to the institution), Petra AMCHOVÁ (203 Czech Republic, belonging to the institution) and Jana RUDÁ (203 Czech Republic, guarantor, belonging to the institution).
Edition FRONTIERS IN BEHAVIORAL NEUROSCIENCE, LAUSANNE, FRONTIERS MEDIA SA, 2024, 1662-5153.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30104 Pharmacology and pharmacy
Country of publisher Switzerland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 3.000 in 2022
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.3389/fnbeh.2023.1305412
UT WoS 001144286000001
Keywords in English AMPA/kainate receptor; CNQX; Nicotine; Methamphetamine; Self-administration; Relapse
Tags 14110516, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 3/5/2024 07:47.
Abstract
CNQX significantly reduced nicotine intake during the maintenance phase, but no effect was revealed on nicotine seeking after forced abstinence. CNQX did not affect methamphetamine taking or seeking. The effect of reducing nicotine taking but not seeking could be explained by different involvement of glutamatergic receptors in various stages of nicotine dependence.
Links
MUNI/A/1342/2022, interní kód MUName: Preklinický a klinický výzkum v oblasti farmakokinetiky, neuropsychofarmakologie a personalizované farmakoterapie v onkologii
Investor: Masaryk University, Preclinical and clinical research in pharmacokinetics, neuropsychopharmacology and personalized pharmacotherapy in oncology
PrintDisplayed: 20/7/2024 19:22